Quick Answer
H101 (Ankerui), China's first and only NMPA-approved oncolytic virus, is an engineered type 5 adenovirus designed to replicate inside tumor cells and lyse them, while converting immunologically "cold" tumors into "hot" ones that respond to immunotherapy. Approved in 2005 and supported by China's 863 national research program, it is positioned mainly as a combination tool — used with TACE for hepatocellular carcinoma, with checkpoint inhibitors, or with radiotherapy/chemotherapy — not as a standalone cure. Three Chinese H101 studies were presented at ASCO 2024, and multiple Chinese expert consensus documents endorse specific combinations. For international patients exploring advanced tumor immunotherapy, it is one of the reasons China is worth evaluating for liver and other solid-tumor cases.
1. What Is H101 (Ankerui)?
H101 (安柯瑞, trade name Ankerui; recombinant human type 5 adenovirus injection) is a genetically engineered oncolytic adenovirus. It was approved by China's NMPA in 2005, making it the first — and to date only — NMPA-approved oncolytic virus product in the country. It was developed by Shanghai Sunway Biotech and supported by China's National 863 High-Tech Program.
It is not a wild-type virus. Three genetic modifications define how it works:
| Modification | Purpose |
|---|---|
| E1B-55kD gene deleted | The virus can replicate only inside tumor cells, lysing them — normal human cells are largely spared, protecting healthy tissue |
| E1B-19kD region deleted | Remodels the tumor immune microenvironment and amplifies systemic antitumor immune responses |
| E1A gene retained | Enhances sensitivity to radiotherapy and chemotherapy |
Two capabilities follow from this design: direct, precise killing of tumor cells and activation of the patient's own immune system.
2. Core Principle: Turning "Cold" Tumors "Hot"
Many hard-to-treat solid tumors are "cold": few immune cells inside the tumor, heavy immunosuppression, and consequently poor responses to PD-1/PD-L1 checkpoint inhibitors. That is a central problem in immunotherapy today.
When H101 enters a tumor, two things happen:
- Direct oncolysis — the virus replicates inside tumor cells, causing them to rupture and release large amounts of tumor antigens.
- Microenvironment remodeling — the released antigens activate dendritic cells and recruit CD8+ effector T cells and NK cells into the lesion, while suppressing regulatory T cells (Tregs) and M2-type suppressive macrophages.
The net effect is to shift an immunologically silent "cold" tumor toward a "hot," T-cell-inflamed one — the same environment in which checkpoint inhibitors work best. This is the underlying rationale for using oncolytic viruses in combination therapy: a tumor that previously resisted immunotherapy may become responsive again.
Oncolytic viruses are characterized by four features: multi-mechanism antitumor activity, activity across multiple solid-tumor types, a generally controllable safety profile, and suitability for combination with interventional, chemotherapy, and immunotherapy approaches.
3. International Recognition: Three Chinese Studies at ASCO 2024
At the American Society of Clinical Oncology (ASCO) 2024 annual meeting, three Chinese clinical studies of H101 were accepted — evidence that international oncology has taken note:
| Study | Setting |
|---|---|
| TROJAN021 | H101 combined with a checkpoint inhibitor for gastric cancer with liver metastases |
| Recurrent/metastatic gynecologic malignancies | Intratumoral H101 injection, observing tumor lesions and immune microenvironment changes |
| Mass-forming intrahepatic cholangiocarcinoma | H101 combined with hepatic arterial infusion chemotherapy |
Beyond the ASCO abstracts, a Fudan University Shanghai Cancer Center team published in Molecular Therapy: Oncolytics (IF 5.3). Their study found that after H101 treatment, CD8+ T-cell infiltration in lesions rose significantly and tumor-specific immunity was activated; they also observed upregulation of PD-L1 on lesions, which mechanistically supports combining the oncolytic virus with checkpoint inhibitors.
4. What Chinese Guidelines Say
Three expert consensus documents — which represent the views of mainland oncology and interventional specialists — reference H101:
《基因重组溶瘤腺病毒治疗恶性肿瘤临床应用中国专家共识（2022版）》(Chinese Expert Consensus on Clinical Application of Recombinant Oncolytic Adenovirus for Malignant Tumors, 2022) — for unresectable hepatocellular carcinoma with Child-Pugh A/B liver function and no extrahepatic spread, initial therapy may consider hepatic arterial infusion of H101 combined with TACE. Multiple real-world studies suggest the combination improves tumor response and prolongs survival compared with TACE alone.
《原发性肝细胞癌经动脉内用药与联合用药中国专家共识（2023版）》(Chinese Expert Consensus on Intra-arterial Drug Use and Combination Therapy for Primary Hepatocellular Carcinoma, 2023, Chinese Journal of Internal Medicine) — recognizes that oncolytic viruses lyse tumor cells and activate tumor-specific antitumor immunity, and endorses arterial-infusion oncolytic-virus combination therapy as an innovative direction in interventional oncology.
《肝细胞癌围手术期免疫治疗多学科协作专家共识（2025版）》(Multidisciplinary Expert Consensus on Perioperative Immunotherapy for Hepatocellular Carcinoma, 2025, Chinese Journal of Digestive Surgery) — proposes that intraoperative local oncolytic-virus perfusion may help control local recurrence; evidence level IIb, an exploratory treatment approach.
All three documents stress that oncolytic-virus combination therapy requires careful patient selection. It is not appropriate for everyone.
5. Safety Profile
Published clinical data describe H101 as generally well tolerated:
- Most common adverse events are low-grade (1-2) fever and injection-site pain, usually resolving within hours without special intervention.
- When combined with TACE for hepatocellular carcinoma, the main difference versus TACE alone was a higher incidence of fever; liver-function indicators were not significantly different — no added liver injury.
- Combined with checkpoint inhibitors, no new serious toxicity was reported.
- Viral-shedding studies found no spread of the virus into the external environment after treatment, suggesting low risk to healthcare staff and the environment.
Individual variation still exists — adverse reactions depend on the patient's baseline condition and the route of administration, and require continuous monitoring by the treating physician.
6. How H101 Is Given, and Access in China
According to published Chinese studies, two main delivery routes are used (educational only, not a treatment recommendation):
- Hepatic arterial infusion — commonly used for liver tumors, often combined with TACE; a 21-day treatment cycle. For hepatocellular carcinoma, the 2022 consensus specifically discusses unresectable disease with Child-Pugh A/B liver function.
- Intratumoral injection — ultrasound- or CT-guided direct injection into the lesion; may be followed by a PD-1 inhibitor for combination therapy.
Because H101 is administered by interventional oncology teams, access is centered at hospitals with strong interventional radiology and oncology programs — typically large academic cancer centers in China's major cities. Eligibility depends on tumor type, stage, organ function, and whether a combination protocol (TACE, checkpoint inhibitor, or local ablation) fits the case.
Is your case a candidate? Send the latest imaging and pathology reports plus your treatment history — we route your case to suitable oncology centers with interventional capacity and get a written assessment back. Get a free hospital recommendation and cost estimate → Start Free Case Review (We reply within 24 hours · 100% confidential · No obligation).
7. What H101 Is Not
Oncolytic virus therapy is still maturing. Real challenges remain: benefit is limited in some patients, resistance can develop, and preventing recurrence after surgery still needs higher-level evidence.
H101 should be understood as an important combination tool, not a standalone "cure." Its value lies in remodeling the tumor's immune microenvironment and creating treatment opportunities for solid-tumor patients for whom standard drugs have underperformed.
Oncolytic virus therapy is currently being applied and explored mainly in China. For patients researching advanced tumor options, it is worth having on your radar — but every treatment decision must be made by an oncology specialist based on tumor type, stage, and overall condition.
8. Frequently Asked Questions
What is H101 (Ankerui), and is it approved in China?
H101 (Ankerui, recombinant human type 5 adenovirus injection) is China's first and only NMPA-approved oncolytic virus product, approved in 2005. It is an engineered adenovirus designed to replicate inside tumor cells and lyse them while sparing normal tissue.
How does oncolytic virus therapy work for "cold" tumors?
The virus replicates inside tumor cells, causing them to lyse and release tumor antigens. This recruits CD8+ T cells and NK cells, reduces suppressive cells, and can convert an immunologically "cold" tumor into a "hot" one that responds better to checkpoint inhibitors.
Which cancers is H101 used for in China?
Published Chinese research covers hepatocellular carcinoma (via hepatic arterial infusion, often combined with TACE), gastric cancer with liver metastases, intrahepatic cholangiocarcinoma, and recurrent/metastatic gynecologic malignancies. It is typically used in combination, not as a standalone cure.
What evidence supports H101?
Three Chinese H101 studies were presented at ASCO 2024, and a Fudan University Shanghai Cancer Center team published in Molecular Therapy: Oncolytics showing increased CD8+ T-cell infiltration and PD-L1 upregulation after treatment. Chinese expert consensus documents endorse arterial-infusion H101 combined with TACE for unresectable hepatocellular carcinoma.
Is oncolytic virus therapy in China safe?
Published data describe it as generally tolerable. The most common side effects are low-grade fever and injection-site pain that usually resolve within hours. Combined with TACE, liver function did not differ significantly from TACE alone; no new serious toxicity was reported with checkpoint inhibitors.
Get a Free Hospital Recommendation & Cost Estimate
Tell us your diagnosis and treatment history — we'll check eligibility for immunotherapy and interventional oncology programs, match you with 2-3 suitable centers, and get written assessments. No obligation, 100% confidential, we reply within 24 hours.
- 📧 Email: contact@chinahospitalsguide.com
- 💬 WhatsApp: +86 157 6310 7083
- 📨 Telegram: @chinahospitalguide
- 💬 WeChat: chinahospitalguide
- 🌐 Start Free Case Review
Medical Disclaimer This article is general educational content only and does not constitute medical advice, a treatment recommendation, or an invitation to seek care. It cannot replace an in-person consultation with a licensed physician. Medications and therapies mentioned reflect publicly published research, literature, and expert consensus only. Every person's condition differs, and whether a given treatment fits must be evaluated by an oncology specialist at a licensed hospital. Do not decide on a treatment plan based on web articles alone. If you are ill, please consult a qualified local clinician.
Information source disclosure This article was prepared with information support from Fosun Pharma, which develops H101 (Ankerui) through its Shanghai Sunway Biotech subsidiary. China Hospitals Guide is an independent hospital-matching platform and does not accept commissions from hospitals or guarantee referrals to any single institution.